FOXO1 and prostate carcinoma: miR-96-5p was found to be abnormally expressed in colorectal cancer, prostate cancer, and several other malignant tumors (41–44) where miR-96-5p can regulate FoxO1 levels and consequently inhibit proliferation (45).